VALLEY CHILDRENS HOSPITAL
- Type
- Teaching hospital
- Where
- Madera, CA
- Medicare CCN
- 053300
- Received
- $162,844 in 124 records, 2020 ($3,519 general, $159,325 research)
- Source
- CMS Open Payments search ↗
On this site
- Nonprofit: VALLEY CHILDRENS HOSPITAL Fuzzy (name and state)
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2020 | General payment | 16 | $3,519 |
| 2020 | Research payment | 108 | $159,325 |
By company
| Company | Records | Amount | Years |
|---|---|---|---|
| VERTEX PHARMACEUTICALS INCORPORATED | 2 | $64,144 | 2020 |
| Novo Nordisk AS | 74 | $26,207 | 2020 |
| ABBVIE INC. | 3 | $16,626 | 2020 |
| Abbott Laboratories | 10 | $16,405 | 2020 |
| Gilead Sciences, Inc. | 1 | $15,300 | 2020 |
| GENZYME CORPORATION | 4 | $9,400 | 2020 |
| Novartis Gene Therapies, Inc. (fka Avexis, Inc.) | 3 | $9,113 | 2020 |
| Cochlear Americas | 8 | $2,108 | 2020 |
| Incyte Corporation | 10 | $1,128 | 2020 |
| Endo Pharmaceuticals Inc. | 1 | $1,000 | 2020 |
| KARL STORZ Endoscopy-America | 4 | $921 | 2020 |
| Vero Biotech Inc. | 1 | $255 | 2020 |
| Masimo Corporation | 2 | $158 | 2020 |
| Stryker Corporation | 1 | $75 | 2020 |
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 108 | $159,325 |
| Grant | 8 | $2,108 |
| Gift | 4 | $918 |
| Food and Beverage | 1 | $255 |
| Education | 3 | $237 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2020-12-31 | Masimo Corporation | $91 | Education | In-kind items and services | SET and rainbow SET Device, Devices | 2020 | |
| 2020-12-31 | Stryker Corporation | $75 | Gift | Cash or cash equivalent | NONE Device, NONE | 2020 | |
| 2020-12-31 | Masimo Corporation | $67 | Education | In-kind items and services | EMMA and ISA Device, Devices | 2020 | |
| 2020-12-10 | Abbott Laboratories | $1,000 | Research payment | Cash or cash equivalent | SJM Masters HP 15mm Rotatable Mechanical Heart Valve Device, Cardiac Arrhythmias and Heart Failure | A Single Arm, Non-randomized, Multi-center Clinical Study of the SJM Masters HP 15mm Rotatable Mechanical Heart Valve as | 2020 |
| 2020-12-10 | Abbott Laboratories | $500 | Research payment | Cash or cash equivalent | Amplatzer Muscular VSD (MuVSD) Occluder Device, Cardiac Arrhythmias and Heart Failure | Closure of Muscular Ventricular Septal Defects (VSDs) With the AMPLATZER Muscular VSD (MuVSD) Occluder - Post Approval S | 2020 |
| 2020-12-10 | Abbott Laboratories | $500 | Research payment | Cash or cash equivalent | Amplatzer Muscular VSD (MuVSD) Occluder Device, Cardiac Arrhythmias and Heart Failure | Closure of Muscular Ventricular Septal Defects (VSDs) With the AMPLATZER Muscular VSD (MuVSD) Occluder - Post Approval S | 2020 |
| 2020-12-10 | Abbott Laboratories | $255 | Research payment | Cash or cash equivalent | Amplatzer Muscular VSD (MuVSD) Occluder Device, Cardiac Arrhythmias and Heart Failure | Closure of Muscular Ventricular Septal Defects (VSDs) With the AMPLATZER Muscular VSD (MuVSD) Occluder - Post Approval S | 2020 |
| 2020-11-12 | Abbott Laboratories | $1,500 | Research payment | Cash or cash equivalent | Amplatzer Muscular VSD (MuVSD) Occluder Device, Cardiac Arrhythmias and Heart Failure | Closure of Muscular Ventricular Septal Defects (VSDs) With the AMPLATZER Muscular VSD (MuVSD) Occluder - Post Approval S | 2020 |
| 2020-11-11 | Novartis Gene Therapies, Inc. (fka Avexis, Inc.) | $1,613 | Research payment | Cash or cash equivalent | ZOLGENSMA Biological, GENE THERAPY | A Prospective, Long-Term Registry of Patients with a Diagnosis of Spinal Muscular Atrophy | 2020 |
| 2020-11-09 | Incyte Corporation | $12 | Research payment | Cash or cash equivalent | A Pilot Study of the Immunological Effects of Neo Adjuvant INCB024360 in Patients with Epithelial Ovarian, Fallopian Tub | 2020 | |
| 2020-11-09 | Incyte Corporation | $12 | Research payment | Cash or cash equivalent | A Pilot Study of the Immunological Effects of Neo Adjuvant INCB024360 in Patients with Epithelial Ovarian, Fallopian Tub | 2020 | |
| 2020-11-09 | Incyte Corporation | $10 | Research payment | Cash or cash equivalent | A Pilot Study of the Immunological Effects of Neo Adjuvant INCB024360 in Patients with Epithelial Ovarian, Fallopian Tub | 2020 | |
| 2020-11-09 | Incyte Corporation | $0 | Research payment | Cash or cash equivalent | A Pilot Study of the Immunological Effects of Neo Adjuvant INCB024360 in Patients with Epithelial Ovarian, Fallopian Tub | 2020 | |
| 2020-11-05 | Vero Biotech Inc. | $255 | Food and Beverage | In-kind items and services | Genosyl Drug, Respiratory Therapy | 2020 | |
| 2020-11-02 | Gilead Sciences, Inc. | $15,300 | Research payment | Cash or cash equivalent | Veklury Drug, COVID-19 | A Phase 2/3 Single-Arm, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Remdesi | 2020 |
| 2020-10-21 | Abbott Laboratories | $550 | Research payment | Cash or cash equivalent | Amplatzer Muscular VSD (MuVSD) Occluder Device, Vascular | Closure of Muscular Ventricular Septal Defects (VSDs) With the AMPLATZER Muscular VSD (MuVSD) Occluder - Post Approval S | 2020 |
| 2020-10-15 | Abbott Laboratories | $500 | Research payment | Cash or cash equivalent | Amplatzer Muscular VSD (MuVSD) Occluder Device, Vascular | Closure of Muscular Ventricular Septal Defects (VSDs) With the AMPLATZER Muscular VSD (MuVSD) Occluder - Post Approval S | 2020 |
| 2020-08-25 | Novo Nordisk AS | $2,000 | Research payment | Cash or cash equivalent | NN8640-4263 | 2020 | |
| 2020-08-25 | Novo Nordisk AS | $180 | Research payment | Cash or cash equivalent | NN8640-4263 | 2020 | |
| 2020-08-18 | Novartis Gene Therapies, Inc. (fka Avexis, Inc.) | $6,500 | Research payment | Cash or cash equivalent | ZOLGENSMA Biological, GENE THERAPY | A Prospective, Long-Term Registry of Patients with a Diagnosis of Spinal Muscular Atrophy | 2020 |
| 2020-08-18 | Novartis Gene Therapies, Inc. (fka Avexis, Inc.) | $1,000 | Research payment | Cash or cash equivalent | ZOLGENSMA Biological, GENE THERAPY | A Prospective, Long-Term Registry of Patients with a Diagnosis of Spinal Muscular Atrophy | 2020 |
| 2020-08-17 | GENZYME CORPORATION | $1,200 | Research payment | Cash or cash equivalent | HECTOROL Drug, Genetic Disease | An Open-Label, Randomized, Parallel Group Study to Assess the Safety and Efficacy of Hectorol (Doxercalciferol Capsules) | 2020 |
| 2020-08-06 | Abbott Laboratories | $7,000 | Research payment | Cash or cash equivalent | SJM Masters HP 15mm Rotatable Mechanical Heart Valve Device, Cardiac Arrhythmias and Heart Failure | A Single Arm, Non-randomized, Multi-center Clinical Study of the SJM Masters HP 15mm Rotatable Mechanical Heart Valve as | 2020 |
| 2020-08-04 | GENZYME CORPORATION | $4,500 | Research payment | Cash or cash equivalent | HECTOROL Drug, Genetic Disease | An Open-Label, Randomized, Parallel Group Study to Assess the Safety and Efficacy of Hectorol (Doxercalciferol Capsules) | 2020 |
| 2020-08-04 | GENZYME CORPORATION | $2,500 | Research payment | Cash or cash equivalent | HECTOROL Drug, Genetic Disease | An Open-Label, Randomized, Parallel Group Study to Assess the Safety and Efficacy of Hectorol (Doxercalciferol Capsules) | 2020 |
| 2020-08-04 | GENZYME CORPORATION | $1,200 | Research payment | Cash or cash equivalent | HECTOROL Drug, Genetic Disease | An Open-Label, Randomized, Parallel Group Study to Assess the Safety and Efficacy of Hectorol (Doxercalciferol Capsules) | 2020 |
| 2020-07-22 | Abbott Laboratories | $1,100 | Research payment | Cash or cash equivalent | Amplatzer Muscular VSD (MuVSD) Occluder Device, Cardiac Arrhythmias and Heart Failure | Closure of Muscular Ventricular Septal Defects (VSDs) With the AMPLATZER Muscular VSD (MuVSD) Occluder - Post Approval S | 2020 |
| 2020-06-30 | Cochlear Americas | $185 | Grant | In-kind items and services | Nucleus Device, Implantable hearing solution | 2020 | |
| 2020-06-22 | Cochlear Americas | $97 | Grant | In-kind items and services | Nucleus Device, Implantable hearing solution | 2020 | |
| 2020-06-04 | Abbott Laboratories | $3,500 | Research payment | Cash or cash equivalent | SJM Masters HP 15mm Rotatable Mechanical Heart Valve Device, Cardiac Arrhythmias and Heart Failure | A Single Arm, Non-randomized, Multi-center Clinical Study of the SJM Masters HP 15mm Rotatable Mechanical Heart Valve as | 2020 |
| 2020-04-27 | ABBVIE INC. | $9,922 | Research payment | In-kind items and services | VENCLEXTA Drug, ONCOLOGY | C19-920 | 2020 |
| 2020-04-27 | ABBVIE INC. | $3,375 | Research payment | In-kind items and services | VENCLEXTA Drug, ONCOLOGY | C19-920 | 2020 |
| 2020-04-27 | ABBVIE INC. | $3,329 | Research payment | In-kind items and services | VENCLEXTA Drug, ONCOLOGY | C19-920 | 2020 |
| 2020-04-23 | Novo Nordisk AS | $3,500 | Research payment | Cash or cash equivalent | NN8640-4263 | 2020 | |
| 2020-03-31 | Novo Nordisk AS | $6,000 | Research payment | Cash or cash equivalent | NN8640-4263 | 2020 | |
| 2020-03-31 | Novo Nordisk AS | $1,500 | Research payment | Cash or cash equivalent | NN8640-4263 | 2020 | |
| 2020-03-31 | Novo Nordisk AS | $500 | Research payment | Cash or cash equivalent | NN8640-4263 | 2020 | |
| 2020-03-31 | Novo Nordisk AS | $500 | Research payment | Cash or cash equivalent | NN8640-4263 | 2020 | |
| 2020-03-11 | Cochlear Americas | $650 | Grant | In-kind items and services | Nucleus Device, Implantable hearing solution | 2020 | |
| 2020-03-11 | Cochlear Americas | $425 | Grant | In-kind items and services | Nucleus Device, Implantable hearing solution | 2020 | |
| 2020-03-11 | Cochlear Americas | $300 | Grant | In-kind items and services | Nucleus Device, Implantable hearing solution | 2020 | |
| 2020-03-11 | Cochlear Americas | $200 | Grant | In-kind items and services | Nucleus Device, Implantable hearing solution | 2020 | |
| 2020-03-11 | Cochlear Americas | $154 | Grant | In-kind items and services | Nucleus Device, Implantable hearing solution | 2020 | |
| 2020-03-11 | Cochlear Americas | $97 | Grant | In-kind items and services | Nucleus Device, Implantable hearing solution | 2020 | |
| 2020-02-15 | VERTEX PHARMACEUTICALS INCORPORATED | $1,375 | Research payment | Cash or cash equivalent | A Study of VX-445 Combination Therapy in CF Subjects Homozygous for F508del (F/F) | 2020 | |
| 2020-02-13 | Incyte Corporation | $1,000 | Research payment | Cash or cash equivalent | A Pilot Study of the Immunological Effects of Neo Adjuvant INCB024360 in Patients with Epithelial Ovarian, Fallopian Tub | 2020 | |
| 2020-02-11 | Endo Pharmaceuticals Inc. | $1,000 | Research payment | Cash or cash equivalent | SUPPRELIN Drug, ENDOCRINOLOGY | A MULTICENTER, OBSERVATIONAL REGISTRY OF PEDIATRIC FEMALE PATIENTS WITH CENTRAL PRECOCIOUS PUBERTY REVCEIVING SUPPRELIN | 2020 |
| 2020-02-10 | KARL STORZ Endoscopy-America | $78 | Education | In-kind items and services | VIDEO-URETERO-RENOSCOPE FLEX XC Device, UROLOGY | 2020 | |
| 2020-02-10 | Incyte Corporation | $37 | Research payment | Cash or cash equivalent | A Pilot Study of the Immunological Effects of Neo Adjuvant INCB024360 in Patients with Epithelial Ovarian, Fallopian Tub | 2020 | |
| 2020-02-10 | Incyte Corporation | $21 | Research payment | Cash or cash equivalent | A Pilot Study of the Immunological Effects of Neo Adjuvant INCB024360 in Patients with Epithelial Ovarian, Fallopian Tub | 2020 | |
| 2020-02-10 | Incyte Corporation | $12 | Research payment | Cash or cash equivalent | A Pilot Study of the Immunological Effects of Neo Adjuvant INCB024360 in Patients with Epithelial Ovarian, Fallopian Tub | 2020 | |
| 2020-02-10 | Incyte Corporation | $12 | Research payment | Cash or cash equivalent | A Pilot Study of the Immunological Effects of Neo Adjuvant INCB024360 in Patients with Epithelial Ovarian, Fallopian Tub | 2020 | |
| 2020-02-10 | Incyte Corporation | $10 | Research payment | Cash or cash equivalent | A Pilot Study of the Immunological Effects of Neo Adjuvant INCB024360 in Patients with Epithelial Ovarian, Fallopian Tub | 2020 | |
| 2020-01-22 | Novo Nordisk AS | $10,000 | Research payment | In-kind items and services | NN8640-4263 | 2020 | |
| 2020-01-22 | Novo Nordisk AS | $831 | Research payment | In-kind items and services | NN8640-4263 | 2020 | |
| 2020-01-22 | Novo Nordisk AS | $250 | Research payment | In-kind items and services | NN8640-4263 | 2020 | |
| 2020-01-22 | Novo Nordisk AS | $250 | Research payment | In-kind items and services | NN8640-4263 | 2020 | |
| 2020-01-22 | Novo Nordisk AS | $150 | Research payment | In-kind items and services | NN8640-4263 | 2020 | |
| 2020-01-22 | Novo Nordisk AS | $17 | Research payment | In-kind items and services | NN8640-4263 | 2020 | |
| 2020-01-22 | Novo Nordisk AS | $17 | Research payment | In-kind items and services | NN8640-4263 | 2020 | |
| 2020-01-22 | Novo Nordisk AS | $17 | Research payment | In-kind items and services | NN8640-4263 | 2020 | |
| 2020-01-22 | Novo Nordisk AS | $17 | Research payment | In-kind items and services | NN8640-4263 | 2020 | |
| 2020-01-22 | Novo Nordisk AS | $17 | Research payment | In-kind items and services | NN8640-4263 | 2020 | |
| 2020-01-22 | Novo Nordisk AS | $17 | Research payment | In-kind items and services | NN8640-4263 | 2020 | |
| 2020-01-22 | Novo Nordisk AS | $17 | Research payment | In-kind items and services | NN8640-4263 | 2020 | |
| 2020-01-22 | Novo Nordisk AS | $17 | Research payment | In-kind items and services | NN8640-4263 | 2020 | |
| 2020-01-22 | Novo Nordisk AS | $17 | Research payment | In-kind items and services | NN8640-4263 | 2020 | |
| 2020-01-22 | Novo Nordisk AS | $17 | Research payment | In-kind items and services | NN8640-4263 | 2020 | |
| 2020-01-22 | Novo Nordisk AS | $17 | Research payment | In-kind items and services | NN8640-4263 | 2020 | |
| 2020-01-22 | Novo Nordisk AS | $17 | Research payment | In-kind items and services | NN8640-4263 | 2020 | |
| 2020-01-22 | Novo Nordisk AS | $17 | Research payment | In-kind items and services | NN8640-4263 | 2020 | |
| 2020-01-22 | Novo Nordisk AS | $17 | Research payment | In-kind items and services | NN8640-4263 | 2020 | |
| 2020-01-22 | Novo Nordisk AS | $17 | Research payment | In-kind items and services | NN8640-4263 | 2020 | |
| 2020-01-22 | Novo Nordisk AS | $17 | Research payment | In-kind items and services | NN8640-4263 | 2020 | |
| 2020-01-22 | Novo Nordisk AS | $17 | Research payment | In-kind items and services | NN8640-4263 | 2020 | |
| 2020-01-22 | Novo Nordisk AS | $17 | Research payment | In-kind items and services | NN8640-4263 | 2020 | |
| 2020-01-22 | Novo Nordisk AS | $17 | Research payment | In-kind items and services | NN8640-4263 | 2020 | |
| 2020-01-22 | Novo Nordisk AS | $17 | Research payment | In-kind items and services | NN8640-4263 | 2020 | |
| 2020-01-22 | Novo Nordisk AS | $17 | Research payment | In-kind items and services | NN8640-4263 | 2020 | |
| 2020-01-22 | Novo Nordisk AS | $9 | Research payment | In-kind items and services | NN8640-4263 | 2020 | |
| 2020-01-22 | Novo Nordisk AS | $7 | Research payment | In-kind items and services | NN8640-4263 | 2020 | |
| 2020-01-22 | Novo Nordisk AS | $7 | Research payment | In-kind items and services | NN8640-4263 | 2020 | |
| 2020-01-22 | Novo Nordisk AS | $7 | Research payment | In-kind items and services | NN8640-4263 | 2020 | |
| 2020-01-22 | Novo Nordisk AS | $7 | Research payment | In-kind items and services | NN8640-4263 | 2020 | |
| 2020-01-22 | Novo Nordisk AS | $7 | Research payment | In-kind items and services | NN8640-4263 | 2020 | |
| 2020-01-22 | Novo Nordisk AS | $7 | Research payment | In-kind items and services | NN8640-4263 | 2020 | |
| 2020-01-22 | Novo Nordisk AS | $7 | Research payment | In-kind items and services | NN8640-4263 | 2020 | |
| 2020-01-22 | Novo Nordisk AS | $7 | Research payment | In-kind items and services | NN8640-4263 | 2020 | |
| 2020-01-22 | Novo Nordisk AS | $7 | Research payment | In-kind items and services | NN8640-4263 | 2020 | |
| 2020-01-22 | Novo Nordisk AS | $7 | Research payment | In-kind items and services | NN8640-4263 | 2020 | |
| 2020-01-22 | Novo Nordisk AS | $7 | Research payment | In-kind items and services | NN8640-4263 | 2020 | |
| 2020-01-22 | Novo Nordisk AS | $6 | Research payment | In-kind items and services | NN8640-4263 | 2020 | |
| 2020-01-22 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | NN8640-4263 | 2020 | |
| 2020-01-22 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | NN8640-4263 | 2020 | |
| 2020-01-22 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | NN8640-4263 | 2020 | |
| 2020-01-22 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | NN8640-4263 | 2020 | |
| 2020-01-22 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | NN8640-4263 | 2020 | |
| 2020-01-22 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | NN8640-4263 | 2020 | |
| 2020-01-22 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | NN8640-4263 | 2020 | |
| 2020-01-22 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | NN8640-4263 | 2020 | |
| 2020-01-22 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | NN8640-4263 | 2020 | |
| 2020-01-22 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | NN8640-4263 | 2020 | |
| 2020-01-22 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | NN8640-4263 | 2020 | |
| 2020-01-22 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | NN8640-4263 | 2020 | |
| 2020-01-22 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | NN8640-4263 | 2020 | |
| 2020-01-22 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | NN8640-4263 | 2020 | |
| 2020-01-22 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | NN8640-4263 | 2020 | |
| 2020-01-22 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | NN8640-4263 | 2020 | |
| 2020-01-22 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | NN8640-4263 | 2020 | |
| 2020-01-22 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | NN8640-4263 | 2020 | |
| 2020-01-22 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | NN8640-4263 | 2020 | |
| 2020-01-22 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | NN8640-4263 | 2020 | |
| 2020-01-22 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | NN8640-4263 | 2020 | |
| 2020-01-22 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | NN8640-4263 | 2020 | |
| 2020-01-22 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | NN8640-4263 | 2020 | |
| 2020-01-22 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | NN8640-4263 | 2020 | |
| 2020-01-22 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | NN8640-4263 | 2020 | |
| 2020-01-22 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | NN8640-4263 | 2020 | |
| 2020-01-22 | Novo Nordisk AS | $1 | Research payment | In-kind items and services | NN8640-4263 | 2020 | |
| 2020-01-22 | Novo Nordisk AS | $1 | Research payment | In-kind items and services | NN8640-4263 | 2020 | |
| 2020-01-13 | KARL STORZ Endoscopy-America | $468 | Gift | In-kind items and services | 2020 | ||
| 2020-01-13 | KARL STORZ Endoscopy-America | $257 | Gift | In-kind items and services | 2020 | ||
| 2020-01-13 | KARL STORZ Endoscopy-America | $117 | Gift | In-kind items and services | 2020 | ||
| 2020-01-01 | VERTEX PHARMACEUTICALS INCORPORATED | $62,769 | Research payment | Cash or cash equivalent | A Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination Therapy | 2020 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Madera, CA, county Madera County, CA, state California; placed by its city name.
| Measure | Place (city or town) Madera, CA | County Madera County, CA | State California |
|---|---|---|---|
| Population B01003 | 67,831 | 160,940 | 39,287,377 |
| Population, 2020 census P1 | 66,224 | 156,255 | 39,538,223 |
| Median age B01002 | 30.4 | 34.6 | 37.9 |
| Under 18 B01001 | 30.8% | 27.1% | 22.0% |
| 65 and over B01001 | 9.6% | 14.4% | 15.7% |
| Households B11001 | 17,526 | 45,379 | 13,548,091 |
| Foreign born B05002 | 25.6% | 20.1% | 27.0% |
| Median household income B19013 | $63,933 | $76,627 | $99,122 |
| Median family income B19113 | $67,479 | $83,389 | $113,346 |
| Per capita income B19301 | $24,200 | $30,077 | $49,513 |
| Poverty rate B17001 | 25.6% | 19.2% | 12.0% |
| Unemployment rate B23025 | 12.6% | 10.1% | 6.6% |
| Civilian labor force B23025 | 29,997 | 69,012 | 20,068,466 |
| Mean commute (minutes) B08013 | 25.7 | 27.9 | 28.7 |
| Bachelor's degree or higher B15003 | 10.9% | 17.9% | 37.1% |
| Housing units B25001 | 18,562 | 51,015 | 14,644,735 |
| Owner-occupied B25003 | 54.7% | 67.5% | 55.9% |
| Renters B25003 | 45.3% | 32.5% | 44.1% |
| Median home value B25077 | $359,900 | $393,200 | $734,700 |
| Median gross rent B25064 | $1,353 | $1,390 | $2,036 |
| White, not Hispanic B03002 | 12.2% | 29.9% | 33.8% |
| Black B03002 | 2.9% | 2.4% | 5.2% |
| Hispanic or Latino B03002 | 81.1% | 60.9% | 40.2% |
| Asian B03002 | 1.3% | 2.4% | 15.3% |
| American Indian and Alaska Native B03002 | 0.1% | 0.4% | 0.3% |
Economy now FRED unemployment 5.1% in Sep 2026 (5.5% a year earlier); per capita personal income $90,957 in 2025, up 30% in five years (+4.3% after inflation); the state; Source: FRED, Federal Reserve Bank of St. Louis.
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Madera, CA.
Comments